Previous studies (48, 49) have also demonstrated that anti-PD-1 agents show better anti-cancer effect than anti-PD-L1 agents in the treatment of advanced cancer, including lung cancer, partly owing to the inherent discrepancy among them. Here, PDCD1 is linked to lung cancer.